Tag:

Yervoy

Latest Headlines

Latest Headlines

U.K. drug reviewers slam BMS' melanoma blockbuster but bless J&J's diabetes pill

The cost-effectiveness agency recommended that Bristol-Myers Squibb's widely embraced Yervoy (ipilimumab) should not be used as a first-line treatment for melanoma. The agency does recommend the drug for second-line treatment, but says BMS needs to do more clinical trials to prove its "clinical effectiveness" for earlier use.

Bristol-Myers impresses with trimmed-down costs, pumped-up sales

Bristol-Myers Squibb's got some pumped-up sales to go along with its slimmed-down focus. In the fourth quarter, revenue increases and decreased costs helped the company beat Wall Street's earnings estimates on the way to zeroing in on its new-look pharma model.

Top 15 Drug Launch Superstars

Herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Read the full report >>

Bristol-Myers melanoma drug Yervoy helps patients live years longer, study finds

When it launched in March 2011, Yervoy became the only drug ever to extend survival in patients with advanced forms of melanoma. Now, new data show just how long the breakthrough drug can extend that survival: A few patients using Yervoy could tack on as much as a decade to their lives, according to a long-term study. And more than a few could see a few extra years.

Bristol-Myers' Yervoy hopes snag on flubbed prostate cancer trial

Bristol-Myers Squibb has hit a speed bump in the road to new uses for its melanoma treatment Yervoy. The drug fell short in a prostate cancer trial, by failing to significantly extend patients' lives. But some of the study data could signal good news from another ongoing test of Yervoy in prostate cancer,  Reuters  reports.

Australia to track Yervoy patients to see if it's worth the $110K price

Australia is paying for Bristol-Myers Squibb's melanoma drug Yervoy. And Yervoy is expensive. So, Australian officials plan to monitor patients treated with it to see whether the drug lives up to its promise. It's an unusual move--and unprecedented in Australia.

Top 20 orphan drugs by 2018

For a long time, pharma companies have looked to large disease populations as the biggest potential revenue streams. But those days are long gone. That perception has shifted, especially with the prescription drug market stagnating in the U.S. and Europe. Orphan drugs--pharmaceutical treatments for rare diseases or disorders--have proven themselves as viable moneymakers, and the industry has taken note. Read the report >>

UPDATED: ASCO: Bayer's Nexavar gets boost, while Roche's Avastin reports mixed

Here's a roundup of news on approved drugs from this year's American Society of Clinical Oncology conference, comprising highlights from FierceBiotech 's weekend coverage as well as recent releases.

Merck's 'breakthrough' PD-1 cancer drug in showdown with Bristol-Myers combo

Merck's team arrived at ASCO with some solid positive data backing their melanoma program for lambrolizumab (MK-3475). The pharma giant is readying a pair of late-stage clinical trials for melanoma and non-small cell lung cancer as they set their sights on completing a speedy set of applications for regulators.

ASCO presentations portend future shock of immunotherapy drug prices

This weekend a slate of biopharma companies will be presenting new data at ASCO, underscoring the big new role that immunotherapy drugs will be playing in the fight against cancer.